spironolactone has been researched along with Focal Segmental Glomerulosclerosis in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aldosterone promotes nephrosclerosis in several rat models, whereas aldosterone receptor antagonism blunts the effect of activation of the renin-angiotensin-aldosterone system (RAAS) on nephrosclerosis, independent of effects on blood pressure." | 1.31 | Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. ( Brown, NJ; Donnert, E; Fogo, AB; Freeman, M; Ma, L; Nakamura, I; Nakamura, S; Vaughan, DE, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ceri, M | 1 |
| Unverdi, S | 1 |
| Altay, M | 1 |
| Unverdi, H | 1 |
| Kurultak, I | 1 |
| Yılmaz, R | 1 |
| Ensari, A | 1 |
| Duranay, M | 1 |
| Kobayashi, N | 1 |
| Hara, K | 1 |
| Tojo, A | 1 |
| Onozato, ML | 1 |
| Honda, T | 1 |
| Yoshida, K | 1 |
| Mita, S | 1 |
| Nakano, S | 1 |
| Tsubokou, Y | 1 |
| Matsuoka, H | 1 |
| Nagase, M | 1 |
| Shibata, S | 1 |
| Yoshida, S | 1 |
| Nagase, T | 1 |
| Gotoda, T | 1 |
| Fujita, T | 1 |
| Brown, NJ | 1 |
| Nakamura, S | 1 |
| Ma, L | 1 |
| Nakamura, I | 1 |
| Donnert, E | 1 |
| Freeman, M | 1 |
| Vaughan, DE | 1 |
| Fogo, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00005757] | 293 participants (Actual) | Observational | 1997-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for spironolactone and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Focal segmental glomerulosclerosis in association with Gitelman syndrome.
Topics: Adult; Dietary Supplements; Diuretics; Gitelman Syndrome; Glomerulosclerosis, Focal Segmental; Human | 2011 |
Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway.
Topics: Animals; Cell Adhesion Molecules; Cytoprotection; Eplerenone; Glomerulosclerosis, Focal Segmental; H | 2005 |
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Topics: Animals; Apoptosis; Biomarkers; Blood Pressure; Eplerenone; Fibrosis; Glomerulosclerosis, Focal Segm | 2006 |
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blotting, Northern; Creatinine; Disease Progre | 2000 |